WO2022266698A1 - Stabilised hypohalous acid solutions - Google Patents
Stabilised hypohalous acid solutions Download PDFInfo
- Publication number
- WO2022266698A1 WO2022266698A1 PCT/AU2022/050440 AU2022050440W WO2022266698A1 WO 2022266698 A1 WO2022266698 A1 WO 2022266698A1 AU 2022050440 W AU2022050440 W AU 2022050440W WO 2022266698 A1 WO2022266698 A1 WO 2022266698A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- solution
- formulation
- stabilised
- afc
- acid
- Prior art date
Links
- 239000002253 acid Substances 0.000 title claims abstract description 35
- 239000000203 mixture Substances 0.000 claims abstract description 70
- 238000009472 formulation Methods 0.000 claims abstract description 60
- QWPPOHNGKGFGJK-UHFFFAOYSA-N hypochlorous acid Chemical compound ClO QWPPOHNGKGFGJK-UHFFFAOYSA-N 0.000 claims abstract description 45
- 238000000034 method Methods 0.000 claims abstract description 40
- 229910052784 alkaline earth metal Inorganic materials 0.000 claims abstract description 24
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 claims abstract description 19
- 229910052799 carbon Inorganic materials 0.000 claims abstract description 18
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims abstract description 17
- 239000003513 alkali Substances 0.000 claims abstract description 13
- 150000001342 alkaline earth metals Chemical class 0.000 claims abstract description 13
- 230000003019 stabilising effect Effects 0.000 claims abstract description 13
- 239000007788 liquid Substances 0.000 claims abstract description 3
- 230000009974 thixotropic effect Effects 0.000 claims abstract description 3
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 claims description 43
- 229910002092 carbon dioxide Inorganic materials 0.000 claims description 21
- 238000011282 treatment Methods 0.000 claims description 20
- 230000000249 desinfective effect Effects 0.000 claims description 17
- 239000001569 carbon dioxide Substances 0.000 claims description 16
- 235000013305 food Nutrition 0.000 claims description 16
- 239000000017 hydrogel Substances 0.000 claims description 14
- 238000005868 electrolysis reaction Methods 0.000 claims description 9
- 238000003860 storage Methods 0.000 claims description 8
- 239000000499 gel Substances 0.000 claims description 6
- 238000004659 sterilization and disinfection Methods 0.000 claims description 5
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 4
- 239000000919 ceramic Substances 0.000 claims description 4
- 239000000463 material Substances 0.000 claims description 4
- 208000017520 skin disease Diseases 0.000 claims description 4
- 239000007921 spray Substances 0.000 claims description 4
- 239000006071 cream Substances 0.000 claims description 3
- 239000006260 foam Substances 0.000 claims description 3
- 239000003897 fog Substances 0.000 claims description 3
- 239000011521 glass Substances 0.000 claims description 3
- 150000004820 halides Chemical class 0.000 claims description 3
- 239000003595 mist Substances 0.000 claims description 3
- 206010012438 Dermatitis atopic Diseases 0.000 claims description 2
- 229910000831 Steel Inorganic materials 0.000 claims description 2
- 201000008937 atopic dermatitis Diseases 0.000 claims description 2
- 229910052742 iron Inorganic materials 0.000 claims description 2
- 229910052573 porcelain Inorganic materials 0.000 claims description 2
- 239000010959 steel Substances 0.000 claims description 2
- 241000124008 Mammalia Species 0.000 claims 2
- 229940104869 fluorosilicate Drugs 0.000 claims 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 abstract description 10
- 238000004519 manufacturing process Methods 0.000 abstract description 8
- 239000000243 solution Substances 0.000 description 175
- 206010052428 Wound Diseases 0.000 description 34
- 208000027418 Wounds and injury Diseases 0.000 description 34
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 19
- -1 halide salt Chemical class 0.000 description 16
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 15
- 239000000460 chlorine Substances 0.000 description 15
- 229910052801 chlorine Inorganic materials 0.000 description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 15
- 210000001519 tissue Anatomy 0.000 description 14
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 11
- 210000004027 cell Anatomy 0.000 description 10
- 239000011780 sodium chloride Substances 0.000 description 10
- SUKJFIGYRHOWBL-UHFFFAOYSA-N sodium hypochlorite Chemical compound [Na+].Cl[O-] SUKJFIGYRHOWBL-UHFFFAOYSA-N 0.000 description 10
- 230000003115 biocidal effect Effects 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 8
- 239000007864 aqueous solution Substances 0.000 description 8
- WQYVRQLZKVEZGA-UHFFFAOYSA-N hypochlorite Chemical compound Cl[O-] WQYVRQLZKVEZGA-UHFFFAOYSA-N 0.000 description 8
- 244000005700 microbiome Species 0.000 description 8
- 239000005708 Sodium hypochlorite Substances 0.000 description 7
- 150000003839 salts Chemical class 0.000 description 7
- 230000008859 change Effects 0.000 description 6
- 238000001802 infusion Methods 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 5
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 5
- 241000894007 species Species 0.000 description 5
- 241000588724 Escherichia coli Species 0.000 description 4
- 230000001580 bacterial effect Effects 0.000 description 4
- 230000006866 deterioration Effects 0.000 description 4
- 229920001903 high density polyethylene Polymers 0.000 description 4
- 239000004700 high-density polyethylene Substances 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 229910052700 potassium Inorganic materials 0.000 description 4
- 239000011591 potassium Substances 0.000 description 4
- 201000004624 Dermatitis Diseases 0.000 description 3
- 206010048768 Dermatosis Diseases 0.000 description 3
- 241000233866 Fungi Species 0.000 description 3
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 3
- 210000004666 bacterial spore Anatomy 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000003792 electrolyte Substances 0.000 description 3
- 239000003102 growth factor Substances 0.000 description 3
- 229910052749 magnesium Inorganic materials 0.000 description 3
- 239000011777 magnesium Substances 0.000 description 3
- 238000007726 management method Methods 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 235000011007 phosphoric acid Nutrition 0.000 description 3
- 239000004033 plastic Substances 0.000 description 3
- 229920003023 plastic Polymers 0.000 description 3
- 210000004215 spore Anatomy 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 208000002874 Acne Vulgaris Diseases 0.000 description 2
- 241000193830 Bacillus <bacterium> Species 0.000 description 2
- 241000193755 Bacillus cereus Species 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 2
- 201000004681 Psoriasis Diseases 0.000 description 2
- 241001303601 Rosacea Species 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 206010000496 acne Diseases 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 210000004102 animal cell Anatomy 0.000 description 2
- 230000036760 body temperature Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 239000004568 cement Substances 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- 238000011109 contamination Methods 0.000 description 2
- 239000000645 desinfectant Substances 0.000 description 2
- 230000002538 fungal effect Effects 0.000 description 2
- 210000005260 human cell Anatomy 0.000 description 2
- 230000000415 inactivating effect Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 238000012417 linear regression Methods 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 229910017604 nitric acid Inorganic materials 0.000 description 2
- 231100000344 non-irritating Toxicity 0.000 description 2
- 238000001139 pH measurement Methods 0.000 description 2
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 2
- 238000004321 preservation Methods 0.000 description 2
- 201000004700 rosacea Diseases 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229940104870 sodium magnesium fluorosilicate Drugs 0.000 description 2
- 235000011149 sulphuric acid Nutrition 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000007704 transition Effects 0.000 description 2
- AZJYLVAUMGUUBL-UHFFFAOYSA-A u1qj22mc8e Chemical compound [F-].[F-].[F-].[F-].[F-].[F-].[F-].[F-].[F-].[F-].[F-].[F-].[F-].[F-].[F-].[F-].[F-].[F-].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].O=[Si]=O.O=[Si]=O.O=[Si]=O.O1[Si](O2)([O-])O[Si]3([O-])O[Si]1([O-])O[Si]2([O-])O3.O1[Si](O2)([O-])O[Si]3([O-])O[Si]1([O-])O[Si]2([O-])O3.O1[Si](O2)([O-])O[Si]3([O-])O[Si]1([O-])O[Si]2([O-])O3.O1[Si](O2)([O-])O[Si]3([O-])O[Si]1([O-])O[Si]2([O-])O3.O1[Si](O2)([O-])O[Si]3([O-])O[Si]1([O-])O[Si]2([O-])O3.O1[Si](O2)([O-])O[Si]3([O-])O[Si]1([O-])O[Si]2([O-])O3 AZJYLVAUMGUUBL-UHFFFAOYSA-A 0.000 description 2
- 230000035899 viability Effects 0.000 description 2
- 238000012371 Aseptic Filling Methods 0.000 description 1
- 241000193738 Bacillus anthracis Species 0.000 description 1
- 241000194106 Bacillus mycoides Species 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 241000193388 Bacillus thuringiensis Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 1
- 241000193163 Clostridioides difficile Species 0.000 description 1
- 206010011985 Decubitus ulcer Diseases 0.000 description 1
- 206010056340 Diabetic ulcer Diseases 0.000 description 1
- 241000002314 Dichotomopilus funicola Species 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000194033 Enterococcus Species 0.000 description 1
- 101710146739 Enterotoxin Proteins 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 206010063560 Excessive granulation tissue Diseases 0.000 description 1
- 241000588915 Klebsiella aerogenes Species 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- BPQQTUXANYXVAA-UHFFFAOYSA-N Orthosilicate Chemical compound [O-][Si]([O-])([O-])[O-] BPQQTUXANYXVAA-UHFFFAOYSA-N 0.000 description 1
- 208000004210 Pressure Ulcer Diseases 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 241000607764 Shigella dysenteriae Species 0.000 description 1
- 206010040943 Skin Ulcer Diseases 0.000 description 1
- 208000002847 Surgical Wound Diseases 0.000 description 1
- 206010042674 Swelling Diseases 0.000 description 1
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 1
- 208000024780 Urticaria Diseases 0.000 description 1
- 208000000558 Varicose Ulcer Diseases 0.000 description 1
- 238000005299 abrasion Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 229940065181 bacillus anthracis Drugs 0.000 description 1
- 229940097012 bacillus thuringiensis Drugs 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 239000003139 biocide Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000011449 brick Substances 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 239000011111 cardboard Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- XTEGARKTQYYJKE-UHFFFAOYSA-N chloric acid Chemical compound OCl(=O)=O XTEGARKTQYYJKE-UHFFFAOYSA-N 0.000 description 1
- 229940005991 chloric acid Drugs 0.000 description 1
- 238000005660 chlorination reaction Methods 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- 239000004927 clay Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000001804 debridement Methods 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 239000000147 enterotoxin Substances 0.000 description 1
- 231100000655 enterotoxin Toxicity 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000013213 extrapolation Methods 0.000 description 1
- 210000000416 exudates and transudate Anatomy 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 238000009408 flooring Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000007760 free radical scavenging Effects 0.000 description 1
- 244000053095 fungal pathogen Species 0.000 description 1
- 230000002070 germicidal effect Effects 0.000 description 1
- 210000001126 granulation tissue Anatomy 0.000 description 1
- 239000011440 grout Substances 0.000 description 1
- 230000009036 growth inhibition Effects 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 231100001261 hazardous Toxicity 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- CUILPNURFADTPE-UHFFFAOYSA-N hypobromous acid Chemical compound BrO CUILPNURFADTPE-UHFFFAOYSA-N 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 229940094522 laponite Drugs 0.000 description 1
- XCOBTUNSZUJCDH-UHFFFAOYSA-B lithium magnesium sodium silicate Chemical compound [Li+].[Li+].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[Na+].[Na+].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].O1[Si](O2)([O-])O[Si]3([O-])O[Si]1([O-])O[Si]2([O-])O3.O1[Si](O2)([O-])O[Si]3([O-])O[Si]1([O-])O[Si]2([O-])O3.O1[Si](O2)([O-])O[Si]3([O-])O[Si]1([O-])O[Si]2([O-])O3.O1[Si](O2)([O-])O[Si]3([O-])O[Si]1([O-])O[Si]2([O-])O3.O1[Si](O2)([O-])O[Si]3([O-])O[Si]1([O-])O[Si]2([O-])O3.O1[Si](O2)([O-])O[Si]3([O-])O[Si]1([O-])O[Si]2([O-])O3 XCOBTUNSZUJCDH-UHFFFAOYSA-B 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000001050 lubricating effect Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 231100000243 mutagenic effect Toxicity 0.000 description 1
- 230000003505 mutagenic effect Effects 0.000 description 1
- 238000009581 negative-pressure wound therapy Methods 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 230000020477 pH reduction Effects 0.000 description 1
- 239000005022 packaging material Substances 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 230000000242 pagocytic effect Effects 0.000 description 1
- 239000000123 paper Substances 0.000 description 1
- 239000011087 paperboard Substances 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 239000011505 plaster Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000019254 respiratory burst Effects 0.000 description 1
- 230000001235 sensitizing effect Effects 0.000 description 1
- 206010040872 skin infection Diseases 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- CDBYLPFSWZWCQE-UHFFFAOYSA-L sodium carbonate Substances [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000012430 stability testing Methods 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 239000001117 sulphuric acid Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 239000008399 tap water Substances 0.000 description 1
- 235000020679 tap water Nutrition 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000010936 titanium Substances 0.000 description 1
- 229910052719 titanium Inorganic materials 0.000 description 1
- 239000012049 topical pharmaceutical composition Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 244000052613 viral pathogen Species 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N59/00—Biocides, pest repellants or attractants, or plant growth regulators containing elements or inorganic compounds
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01P—BIOCIDAL, PEST REPELLANT, PEST ATTRACTANT OR PLANT GROWTH REGULATORY ACTIVITY OF CHEMICAL COMPOUNDS OR PREPARATIONS
- A01P1/00—Disinfectants; Antimicrobial compounds or mixtures thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23B—PRESERVING, e.g. BY CANNING, MEAT, FISH, EGGS, FRUIT, VEGETABLES, EDIBLE SEEDS; CHEMICAL RIPENING OF FRUIT OR VEGETABLES; THE PRESERVED, RIPENED, OR CANNED PRODUCTS
- A23B7/00—Preservation or chemical ripening of fruit or vegetables
- A23B7/14—Preserving or ripening with chemicals not covered by groups A23B7/08 or A23B7/10
- A23B7/153—Preserving or ripening with chemicals not covered by groups A23B7/08 or A23B7/10 in the form of liquids or solids
- A23B7/157—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L3/00—Preservation of foods or foodstuffs, in general, e.g. pasteurising, sterilising, specially adapted for foods or foodstuffs
- A23L3/34—Preservation of foods or foodstuffs, in general, e.g. pasteurising, sterilising, specially adapted for foods or foodstuffs by treatment with chemicals
- A23L3/3454—Preservation of foods or foodstuffs, in general, e.g. pasteurising, sterilising, specially adapted for foods or foodstuffs by treatment with chemicals in the form of liquids or solids
- A23L3/358—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/20—Elemental chlorine; Inorganic compounds releasing chlorine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
- A61L2/0005—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts
- A61L2/0082—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts using chemical substances
- A61L2/0088—Liquid substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
- A61L2/16—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor using chemical substances
- A61L2/18—Liquid substances or solutions comprising solids or dissolved gases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/02—Local antiseptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2101/00—Chemical composition of materials used in disinfecting, sterilising or deodorising
- A61L2101/02—Inorganic materials
- A61L2101/06—Inorganic materials containing halogen
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Definitions
- the present invention relates to stabilised solutions and formulations of hypohalous acid, such as hypochlorous acid (HOCI), as well as methods for their production and use.
- hypohalous acid such as hypochlorous acid (HOCI)
- the solution finds use for cleaning and/or disinfecting surfaces, food such as fruit, vegetables and crops, or mammalian tissues (including wounds).
- the solutions further find use in the preservation of agricultural products and cut flowers.
- Hypochlorous acid is an oxidant and biocide that is produced by the human body’s natural immune system to fight infection. Hypochlorous acid is generated as the final step of the Oxidative Burst Pathway, with large quantities of hypochlorous acid being released into the phagocytic vesicles to destroy the invading microorganisms. It is considered that hypochlorous acid exerts its biocidal effect by attacking the surface and plasma membrane proteins, impairing transport of solutes and the salt balance of bacterial cells (Pieterson et al., Water SA, 22(1): 43-48 (1996)).
- Escherichia coli exposed to hypochlorous acid lose viability in less than 100 ms due to inactivation of many vital systems (Fair et al., J. Am. Water Works Assoc. 1051-1061 (1940)).
- Hypochlorous acid at 2.6 ppm caused 100% growth inhibition of E. coli in dilute bacterial suspensions in about 5 minutes (Chesney et al., J. Bacteriol. 2131-2135 (1996)).
- 100% kill in 5 minutes requires only 0.08 ppm for A. aerogenes, 0.06 ppm for S. typhosa. 0.05 ppm for S. dysenteriae, and 0.03 ppm for E. coli.
- hypochlorous acid is biocidal to microorganisms, it is not significantly toxic to human or animal cells, at least partly because human and animal cells have extensive and highly effective defence mechanisms known as the Antioxidant Defense System (ADS).
- ADS Antioxidant Defense System
- Hypohalous acid has a wide range of applications where it is important to control microbial contamination, such as for the care and management of wounds, disinfection of hard surfaces such as medical or dental equipment, food safety and processing, water treatment, as well as other industrial and agricultural applications.
- Dakin’s solution for wound care which is a diluted sodium hypochlorite solution (0.5%) prepared by mixing sodium hypochlorite (5.25%), sodium bicarbonate/carbonate (1%), and clean tap water.
- Dakin’s solution has a high pH, and thus causes pain and burning in wound treatment along with rashes, itching, swelling, hives, and/or blisters.
- Dakin’s solution is unstable and unsuitable for clinical use at lower pH’s ( ⁇ 8.5).
- MicrocynTM solution Another alternative is the MicrocynTM solution. While MicrocynTM has a 2-year shelf life, it suffers from a limited level of available free chlorine (AFC) of about 80 ppm (pH of 7.4), and lower percent of hypochlorous acid, which may limit its biocidal effectiveness. EcaFloTM is available for hard surface disinfection. This solution contains equimolar amounts of hypochlorite and hypochlorous acid in addition to high sodium chloride content. The pH of the solution is around 7.5 and the solution has an AFC content of approximately 460 ppm. The solution has a relatively short shelf life of 30 days.
- AFC free chlorine
- hypohalous acid solution that has a high AFC content, has sufficient stability and/or other properties required to be commercially useful in medical and other commercial settings, and is not irritating or harmful to humans, Panicheva et al.
- WO 2012/129161 have proposed a stabilised solution or formulation packaged in a container for storage or sale, comprising hypochlorous acid and a stabilising amount of dissolved inorganic carbon (DIC) incorporated in the form of a bicarbonate or carbonate of an alkali or alkaline earth metal, wherein the solution or formulation has an available free chlorine (AFC) content of from about 10 to about 10,000 parts per million, a pH of from about 4.0 to 7.0, a DIC-to-AFC molar ratio of from 5:1 to 1 :5, and wherein the container is minimally permeable to CO2 or O2.
- AFC available free chlorine
- the method for obtaining the stabilised solution or formulation involves incorporating the DIC (e.g., in the form of carbonate or bicarbonate) by adding it to an electrolyte for electrochemical treatment, or incorporating the DIC (e.g., in the form of carbonate or bicarbonate) by directly adding it to an electrolysed solution comprising hypohalous acid (e.g., HOCI).
- hypohalous acid e.g., HOCI
- Panicheva et al. (WO 2012/129161) teach that the stabilised hypochlorous acid solutions (e.g., solutions of greater than 90%, 95%, or 97% HOCI) may be obtained by electrolysis of a saline solution as described in U.S. Patent 7,276,255 or can be prepared by any suitable method or apparatus by incorporating the bicarbonate or carbonate into the dry electrolyte or the solution for electrolysis.
- the carbonate or bicarbonate can be added to the dry electrolyte in accordance with the desired AFC content of the resulting solution.
- Hypochlorous acid solutions may be prepared by passing saline solution containing the carbonate/bicarbonate over coated titanium electrodes separated by a semi-permeable ceramic membrane at a current of about 6 to 9 Amps. Electrochemical treatment of saline is described, for example, in U.S. Patent 7,303,660, U.S. Patent 7,828,942, and U.S. Patent 7,897,023.
- a bicarbonate or carbonate of an alkali or alkaline earth metal When dissolved in water, a bicarbonate or carbonate of an alkali or alkaline earth metal imparts an alkaline pH to the solution.
- DIC dissolved inorganic carbon
- a particular electrolysis apparatus comprising one or more electrolytic cells, each of which comprises an anode, a cathode and a separator (diaphragm or membrane) capable of avoiding mixing between the solution treated at the anode and the one treated at the cathode.
- the saline solution i.e., a solution containing an alkali or alkaline earth halogenide
- the electrolytic treatment on the anode side of the electrolytic cell above described may allow to lower the solution pH up to acidic values (i.e. lower than 7), and thus to obtain a solution or formulation with the characteristics described by Panicheva et al. (WO 2012/129161).
- this can only be obtained by using an electrolysis apparatus in which the anode and cathode compartments are kept separated by using a diaphragm or a membrane.
- the present invention relates to a stabilised hypohalous acid solution or formulations thereof, which may be conveniently packaged for sale, or stored for later use on demand.
- the invention further relates to methods of making the stabilised hypohalous acid solution or formulation thereof, as well as methods of use for disinfecting mammalian tissue, including wounds and burns, disinfecting or cleansing hard surfaces, treating (e.g., preserving and/or disinfecting) food products or cut flowers, among other uses.
- the invention provides a stabilised solution or formulation packaged in a container for storage or sale, comprising hypochlorous acid and a stabilising amount of dissolved inorganic carbon (DIC) incorporated in the form of carbonic acid or as a bicarbonate of an alkali or alkaline earth metal, wherein the solution or formulation has an available free chlorine (AFC) content of from about 10 to about 10,000 parts per million, a pH of from about 4.0 to 6.75, a DIC-to-AFC molar ratio of from 10:1 to 5:1 , and wherein the container is minimally permeable to CO2 or O2.
- AFC available free chlorine
- the present invention provides a method for preparing the stabilised solution or formulation according to the first aspect of the invention, comprising: incorporating the DIC into the solution or formulation, in amounts sufficient to stabilise the solution or formulation for at least six months.
- the present invention provides a method for disinfecting or treating a mammalian tissue, the method comprising applying the solution or formulation to a mammalian tissue in need of disinfection or treatment.
- the present invention provides a method for disinfecting or cleansing a hard surface comprising applying the stabilised solution or formulation according to the first aspect of the invention to the hard surface, and optionally, wherein the hard surface comprises porcelain, glass, steel, iron, ceramic or polymeric material.
- the present invention provides a method of treating a food product comprising the application of the stabilised solution or formulation according to the first aspect of the invention to the food product, and optionally, wherein the solution is applied as a mist, fog, spray, or ice.
- the solution incorporates a stabilising amount of dissolved inorganic carbon (DIC), which can be in the form of carbonic acid or as a bicarbonate of an alkali or alkaline earth metal.
- DIC dissolved inorganic carbon
- the solution may have an available free halide (AFC) content of from about 10 to about 10,000 parts per million, and a pH of from about 4.0 to about 6.75.
- AFC available free halide
- the solution has a pH of from about 6.1 to about 6.75.
- the solution contains hypochlorous acid, and is prepared by electrolysis of saline.
- the solution is stabilised, as determined by its limited change in pH and/or AFC over time, for at least one month, but in various embodiments, the solution is stabilised for at least six months, at least one year, or more.
- dissolved inorganic carbon is incorporated into the solution at a level of about 10:1 to about 5:1 molar ratio relative to the AFC content.
- dissolved inorganic carbon may be added at a level of about 6:1 , about 6.5:1 , or about 7:1 or at a larger molar ratio relative to the AFC content.
- the solution may comprise HOCI produced by electrolysis of saline, and the solution may have an AFC content of from about 100 to about 500 parts per million, a pH in the range of about 5 to about 6.75, a salinity of about 0.02% to about 1.0%, and an amount of dissolved inorganic carbon in the range of about 700 mg/L to about 5000 mg/L.
- the salinity of the solution does not impact the amount of dissolved inorganic carbon needed for solution stabilisation.
- the HOCI solution is formulated as a hydrogel.
- the method involves incorporating the dissolved inorganic carbon (e.g., in the form of carbonic acid or as a bicarbonate of an alkali or alkaline earth metal) by addition of carbon dioxide to a solution comprising an alkali or alkaline earth hypohalite (e.g., NaOCI).
- a solution comprising an alkali or alkaline earth hypohalite e.g., NaOCI
- an electrolysed solution or other hypohalite solution may be diluted with carbonated water (i.e., water that has been infused with carbon dioxide gas under pressure) or with an aqueous solution comprising carbon dioxide, or even directly infused with gaseous carbon dioxide.
- the electrolysed solution or other hypohalite solution may be diluted (to have the desired AFC content) and then added with carbonated water or directly infused with gaseous carbon dioxide.
- the latter is an effective method for production of low ionic strength hypohalous acid solutions, especially for hydrogel formulations.
- Other embodiments disclosed herein relate to a method for treating a skin condition, including dermatosis, rosacea, skin infection, skin allergy, psoriasis, or acne.
- the HOCI may be formulated as a hydrogel.
- Figure 1 shows the relative percentage of the HOCI and NaOCI species present in a free chlorine aqueous solution at a temperature of 20 D C and 0.1 M ionic strength, as a function of pH (Dissociation of hypochlorous acid, in White’s Handbook of Chlorination and Alternative Disinfectants (5 th edition), Black & Veatch Corporation, 2010).
- Figures 2A and 2B show the change in AFC and pH over storage time of bottled aqueous solutions of free chlorine (produced by electrochemical treatment of a NaCI solution), whose pH was initially adjusted at about 7 with hydrochloric acid; different aliquots of the same solution were bottled in HDPE containers, stored at 40°C to accelerate the deterioration of the solution and kept unopened until measurement.
- the data shown are averages of three values; also shown is the linear regression (solid line) with 95% prediction intervals (broken lines).
- Figures 3A and 3B show the change in AFC and pH over storage time of aqueous solutions of free chlorine (produced by electrochemical treatment of a NaCI solution), whose pH was initially adjusted at about 6.7 by direct infusion with gaseous carbon dioxide; different aliquots of the same solution were bottled in HDPE containers and stored at room temperature. Bottles were stored at 40°C to accelerate the deterioration of the solution and kept unopened until measurement; the data shown are averages of three values, along with the non-linear regression (solid line) with 95% prediction intervals (broken lines).
- the present invention provides a stabilised hypohalous acid solution or formulation thereof, which may be conveniently packaged for sale, or stored for later use on demand.
- the invention further provides methods of making the stabilised hypohalous acid solution, as well as methods of use for disinfecting mammalian tissue, including wounds and bums, disinfecting or cleansing surfaces, or treating or preserving food products or cut flowers, among other uses.
- the invention provides a stabilised hypohalous acid solution or formulation thereof.
- the solution incorporates a stabilising amount of dissolved inorganic carbon (DIC), such as carbonic acid or a bicarbonate of an alkali or alkaline earth metal.
- DIC dissolved inorganic carbon
- the solution may have an available free chlorine (AFC) content of from about 10 to about 10,000 parts per million, and a pH of from about 4.0 to about 6.75.
- AFC available free chlorine
- the solution contains hypochlorous acid, and is prepared by electrolysis of saline.
- the solution is stabilised, as determined by its change in pH and/or AFC over time, for at least one month, but in various embodiments, the solution is stabilised for at least six months, at least one year, or more.
- hypohalous acid may be produced chemically in accordance with some embodiments (e.g., by acidification of hypohalite), the hypohalous acid may also be produced electrochemically.
- the hypohalite solution may be generated by electrolysis of a halide salt, such as sodium chloride, and may comprise a mixture of oxidising species such as predominantly sodium hypochlorite and hypochlorous acid.
- Hypochlorous acid and hypochlorite are in equilibrium and the position of the equilibrium is determined predominantly by the pH (that is, pH affects the concentration of each component).
- An electrolysed sodium chloride solution with a pH of 8.8 to 10.0 has a purity of about > 95% sodium hypochlorite (see Figure 1); by reducing the pH to less alkaline values, the available free chlorine content can be converted into the more effective hypochlorous acid form.
- the pH-adjusted solution may have a pH of from about 4.0 to about 7.5, but in certain embodiments has a pH of from about 4.4 to about 6.75, or a pH of from about 5 to about 6.75, or a pH of from about 5.4 to about 6.4, or a pH of from about 6.0 to about 6.4.
- the solution will contain mostly (> 95%) hypochlorous acid with respect to hypochlorite (see again Figure 1).
- any suitable acid that does not react with the hypohalite can be used; for example, the following acids may be considered: hydrochloric acid (HCI), sulphuric acid (H2SO4), chloric acid (HCIO3), perchloric acid (HCIO4), nitric acid (HNO3), phosphoric acid (H3PO4), acetic acid (CH3COOH), carbonic acid (H2CO3), boric acid (H3BO3).
- HCI hydrochloric acid
- H2SO4 sulphuric acid
- H2SO4 chloric acid
- HCIO3 chloric acid
- HCIO4 perchloric acid
- HNO3 nitric acid
- H3PO4 phosphoric acid
- acetic acid CH3COOH
- carbonic acid H2CO3
- boric acid H3BO3
- the final solution may comprise or consist essentially of hypochlorous acid as the active agent, in some embodiments it may contain other hypohalous acids (e.g., HOBr, or mixture thereof). In some embodiments, the solution contains other oxidising or radical producing species such as a hypohalite (e.g., hypochlorite), hydroxide, H2O2 and O3, among others.
- hypohalite e.g., hypochlorite
- hydroxide e.g., H2O2 and O3, among others.
- the biocidal activity of the solution can be expressed in terms of available free chlorine or AFC. While the invention is applicable to an AFC range of from about 10 to about 10,000 ppm (or to about 5,000 ppm), in certain embodiments, the solution has a relatively high AFC content and is suitable for use with mammalian tissues or agricultural products. For example, the solution may have an AFC content of from about 100 to 1,000 ppm, or 100 to 500 ppm, or about 150 to about 250 ppm. Other AFC levels may be employed and may be selected based upon the intended application. For example, without any limitation, for surface disinfection the AFC may be in the range of about 140 to about 2,000 ppm, or about 400 to about 1 ,000 ppm.
- the solution comprises a stabilising amount of DIC, which is added as carbon dioxide; by reacting with the excess alkalinity, the DIC may finally be present as a bicarbonate or carbonate of alkali or alkaline earth metal, such as, for example, sodium, potassium, calcium, or magnesium.
- the DIC is incorporated at a “stabilising amount”, which can be determined with reference to the change in the pH or AFC content of the solution over time.
- the solution is considered stabilised if the amount of AFC does not drop below about 60% of the initial value over a period of about 6 months.
- the AFC content is stabilised for at least one year from the production date of the solution.
- the solution should be stored at 25°C or at 20°C or less for greater stability (i.e., 25°C and 20 D C are the reference temperatures for determination of stability).
- solutions are packaged in FIDPE or PET bottles, stored in the dark and kept unopened.
- Accelerated tests can be performed by storing the solution at a higher temperature, and the shelf-life predicted from accelerated data by extrapolation; for example, storing the solution at 15 °C above normal storage conditions (storage conditions for Australia are considered to be the temperatures of 25 - 30 °C), a time period of 3 months gives a possible shelf-life prediction of 18 months (TGA instructions for disinfectant testing, version 2.1 , March 2020 - Australian Government, Department of Health, Therapeutic Goods Administration).
- the stabilising amount of DIC can be determined with reference to the final pH of the solution.
- the stabilising amount of DIC is incorporated into the hypohalite solution in such a way as to lower the pH of the solution to 6.75 or less.
- an electrolysed solution or other hypohalite solution may be diluted with carbonated water (i.e., water that has been infused with carbon dioxide gas under pressure) or diluted with an aqueous solution comprising carbon dioxide, or even directly infused with carbon dioxide gas under pressure.
- the electrolysed solution or other hypohalite solution may be diluted to the desired AFC content and then added with carbonated water or directly infused with carbon dioxide gas under pressure. The latter is an effective method for production of low ionic strength hypohalous acid solutions, especially for hydrogel formulations.
- DIC dissolved inorganic carbon
- solutions prepared by electrochemically treating a sodium chloride solution (as opposed to sodium hypochlorite solutions obtained by diluting a commercial sodium hypochlorite solution) have distinct properties, and the stabilising effect obtained by adding DIC can be distinct.
- the addition of DIC provides enhanced biocidal effectiveness for treating microorganism or biofilms, especially in the presence of high organic load.
- hypohalous acid solution may be in the form of a liquid
- the solution may take the form of a cream, a thixotropic gel (e.g. silicate-based gel), and/or foam by the addition of conventional ingredients known in the art.
- a thixotropic gel e.g. silicate-based gel
- foam by the addition of conventional ingredients known in the art.
- topical formulations of electrochemical solutions are disclosed in US 2005/0196462, which is hereby incorporated by reference in its entirety. In these embodiments, the formulation is better contained around the application site by limiting solution run-off.
- convenient applicators for creams, foams, and the like are known, and may be used in accordance with the present invention. Since the solutions of the invention provide the potential for low conductivity, even with relatively high AFC content, and at “skin- friendly” pH levels, the solutions of the invention are particularly suitable for hydrogel formulations.
- the composition has an AFC content of greater than about 150 ppm, greater than about 200 ppm, greater than about 250 ppm, greater than about 300 ppm, or greater than about 400 ppm.
- the formulation may have a conductivity of from about 0.3 mS/cm to about 12 mS/cm, such as from about 0.5 mS/cm to about 10 mS/cm in some embodiments.
- hydrogel formulations in some embodiments have a pH of from about 5 to about 7, or from about 6 to about 6.5 in other embodiments.
- the hydrogels may be prepared from silicate- based carriers, such as sodium magnesium fluorosilicate (e.g., from about 0.5% to about 5%), and may employ an additional buffer for targeting the pH .
- An exemplary buffer is phosphoric acid.
- the stabilised solutions may be packaged for storage or sale, using any suitable container, such as any suitable plastic or glass bottles, or bags (e.g., plastic bags), tubes, or cans (e.g., spray or aerosol).
- the packaging material has minimal gas permeability, including by species such as CO2 and O2.
- the containers may be transparent, or opaque so that they are minimally penetrable by light, and may be of any unit volume, such as about 50 ml_, about 100 ml_, about 125 ml_, about 250 ml_, about 0.5 litre, about 1 litre, about 5 litres, about 10 litres, or greater.
- the hypochlorous acid solution of the invention may also be hypertonic, hypotonic, or isotonic with respect to physiological fluids (blood, plasma, tears, etc.).
- the solution may contain varying levels of salinity, such as from 0.01 to about 2.0%.
- the solution contains from about 0.02% to about 0.9% w/v NaCI when intended for use in medicine.
- the solution may be a normal saline solution (about 0.91% w/v NaCI).
- the solution may contain from about 0.01 to 2.0% w/v of one or more salts, such as a halide salt, e.g. NaCI, KCI, or a mixture of salts or halide salts.
- the salt or halide salt may be a salt of an alkali metal or alkaline earth metal, such as sodium, potassium, calcium, or magnesium.
- the electrolysed solution is generated using a mixture of physiologically balanced salts, as disclosed in U.S. Patent 6,426,066, which is hereby incorporated by reference in its entirety.
- Such salts may include potassium halides (e.g., KCI) and magnesium halides (e.g., MgC ).
- an electrolysed solution or other hypohalite solution may be diluted with carbonated water or an aqueous solution comprising dissolved inorganic carbon in the form of carbon dioxide.
- the diluted hypohalite solution e.g., having the desired AFC content
- the latter is an effective method for production of low ionic strength hypohalous acid solutions, especially for hydrogel formulations.
- Still other aspects of the invention provide methods of disinfecting or cleansing a mammalian tissue, such as a wound or burn, or disinfecting or cleansing a hard surface, or for treating or preserving a food product or cut flowers. Due to the stability of the hypohalous acid solutions, such methods need not be performed proximately to the production of the biocidal solution, and the solution may be prepared well in advance of its use.
- the solutions and formulations of the invention may be used as sterilising, disinfecting and biocidal solutions for human and animal care.
- the solutions are non-hazardous, non-irritating, non-sensitising to the skin, non-irritating to the eyes, not harmful if swallowed, and show no evidence of mutagenic activity.
- the method of the invention provides for moistening, lubricating, irrigating, cleaning, deodorising, disinfecting, or debriding a wound by rinsing, washing or immersing the wound, with or in, the stabilised hypohalous acid solutions, or by applying the solution to the wound and/or wound dressing.
- the wound may or may not be infected, and thus the method of the invention is useful for treating infected wounds and useful for preventing infection of uninfected wounds.
- the invention provides a convenient means for wound care and management and may be used in combination with the apparatus and methods described in U.S. 2010/030132, which is hereby incorporated by reference in its entirety.
- the method may comprise supplying the stabilised solution to a wound site by one or more of soak, scrub, pulsed lavage, hydrosurgery, and ultrasound to effectively debride and disinfect a wound or tissue.
- the solution may be delivered before, during and/or after negative pressure wound therapy to promote proper wound healing physiology.
- the method may employ a wound dressing for coordinating debridement by infusion of hypochlorous acid with negative pressure therapy.
- the invention may be used in combination with a wound treatment apparatus and/or wound dressing.
- the invention allows for an initial stabilised hypochlorous acid solution soak and/or scrub to both debride and disinfect the wound or tissue, followed by the application of negative pressure to the wound or tissue using the stabilised hypochlorous acid solution as an irrigating agent to control wound bioburden, remove excess exudate, and promote formation of granulation tissue.
- the method also involves seamless transition to the stabilised hypohalous acid solution infusion (e.g., active or passive infusion without negative pressure).
- seamless transition can be effected via a wound dressing which allows for controlled infusion of stabilised hypochlorous acid solution with controlled vacuum source.
- continued cell proliferation and regeneration continues without disruption of the wound bed, once the endpoints of negative pressure therapy have been obtained.
- the wound needing care is a stage l-IV pressure ulcer, stasis ulcer, diabetic ulcer, post-surgical wound, burn, cut, abrasion, or a minor irritation of the skin.
- the wound is rinsed, washed, or immersed in the solution periodically over at least two weeks, but treatment may continue periodically for over about 4 weeks, about 9 weeks, or more.
- the wound in some embodiments, is rinsed with the solution at least once a week, but may be treated with the solution at least twice a week, or more frequently.
- the stabilised hypohalous acid solution may be delivered to the wound at room temperature
- the solution may alternatively be heated, for example, to body temperature or about body temperature.
- the solution is comfortable and soothing for the patient, and is more effective.
- the invention provides a method for treating an infected or colonised wound, tissue, surgical cavity, or bone, and a method for reducing wound bioburden.
- the treatment solution in accordance with the invention is generally effective for killing or inactivating a broad spectrum of bacterial, fungal, and viral pathogens, including S. aureus, P. aeruginosa, E. coli, Enterococcus spp., C. difficile, and Candida spp..
- the solution does not produce resistant species, making the methods desirable over the delivery of traditional antibiotics.
- the solution of the invention is particularly suitable for use in conjunction with stem cell and growth factor therapy, including the use of genetically engineered cells and engineered tissue and allografts and organs for transplant in various treatments.
- the solution or formulation thereof is applied for the control of inflammation, including an inflammatory reaction or hyper-inflammation of the skin.
- the solution or formulation thereof may be applied for use in a method as described in U.S. 2007/0196357 or U.S. 2010/0285151, which are hereby incorporated by reference.
- the solution or composition of the invention is applied (e.g., to an affected area) for treatment of a patient having a dermatosis, atopic dermatitis, skin allergy, rosacea, psoriasis, or acne, among others.
- the solution may be formulated as a hydrogel, for example, as described elsewhere herein.
- this invention may be used against microbes on surfaces because of its fast activity against bacterial spores, fungi, and other resistant microorganisms. Because of its effectiveness and the speed at which it acts, the invention meets a substantial public health need, and one that is not adequately addressed by current commonly used antimicrobial agents. Accordingly, application of the solution to various surfaces and materials is useful to control microbial contamination, not only for the care and management of wounds, but for disinfecting hard surfaces such as medical or dental equipment, preserving and decontaminating food products, water treatment, as well as other industrial and agricultural applications.
- the solution or composition of the invention is applied to crops (pre- or post-harvest) or cut flowers for their preservation and/or for improving the overall quality of the product.
- the solution is potassium based and has one or more utilities (e.g., methods of use) as disclosed in PCT/US2011/43590, which is hereby incorporated by reference in its entirety.
- the solution can be applied as a mist, fog, spray, or ice.
- Bacterial spores have a unique chemical composition of spore layers that make them more resistant than vegetative bacteria to the antimicrobial effects of chemical and physical agents.
- the unique chemical composition of fungal cells, especially mould spores makes them more resistant to chemical and physical agents than other microorganisms. This resistance can be particularly troublesome when the spores or fungi are located on surfaces such as food, food contact sites, ware, hospitals and veterinary facilities, surgical implements, and hospital and surgical linens and garments.
- Control of the mould Chaetomium funicola, and of bacterial spore-forming microorganisms of the Bacillus species can be especially important during food packaging, particularly during cold or hot aseptic filling of food and beverage products.
- Microorganisms of the Bacillus species include Bacillus cereus, Bacillus mycoides, Bacillus subtilis, Bacillus anthracis, and Bacillus thuringiensis. These latter microorganisms share many phenotypical properties, have a high level of chromosomal sequence similarity, and are known enterotoxin producers. Bacillus cereus is one of the most problematic because it has been identified as possessing increased resistance to germicidal chemicals used to decontaminate environmental surfaces.
- the term “surface” refers to both hard and soft surfaces and includes, but are not limited to, tile grout, plaster, drywall, ceramic, cement, clay, bricks, stucco, plastic, wallpaper, fabric, tiles, cement and vinyl flooring, heating and/or cooling fins, filters, vanes, baffles, vents, crevices in walls or ceilings, paper and wood products such as lumber, paper, and cardboard, woven products such as blankets, clothing, carpets, drapery and the like.
- the term surface also includes human surfaces, animal surfaces, military equipment, transportation equipment, children’s items, plant surfaces, seeds, outdoor surfaces, soft surfaces, air, wounds, and medical instruments, and the like.
- Example 1 Solutions of free chlorine with neutral pH
- Figures 2A and 2B show averages of three AFC and pH measurements for aqueous solutions of free chlorine (AFC « 350 ppm, initial pH » 9.7) produced by electrochemical treatment of a diluted saline, and then pH adjusted to about 7 with hydrochloric acid.
- AFC « 350 ppm, initial pH » 9.7 aqueous solutions of free chlorine (AFC « 350 ppm, initial pH » 9.7) produced by electrochemical treatment of a diluted saline, and then pH adjusted to about 7 with hydrochloric acid.
- Several aliquots of the same solution were bottled in HDPE bottles, stored at 40°C to accelerate the deterioration of the solution, and kept unopened until measurement.
- both the pH and AFC content were not stabilised over the long term. For example, the solutions were not stabilised for more than about one month.
- Example 2 Stabilised solutions of free chlorine containing dissolved inorganic carbon
- an aqueous solution of free chlorine (AFC ⁇ 380 ppm, initial pH * 9.8) was produced by electrochemical treatment of a diluted saline, and then pH-adjusted to approximately 6.7 by direct infusion with gaseous carbon dioxide. Based on the required shift in pH (from 9.8 to 6.7) and AFC content (as the pH changes, part of the added acidity is consumed by the chemical equilibrium that transforms sodium hypochlorite into hypochlorous acid), the DIC-to-AFC molar ratio is estimated at approximately 6.8:1.
- Several aliquots of the same solution were bottled in HDPE bottles, stored at 40°C to accelerate the deterioration of the solution, and kept unopened until measurement.
- Figure 3A and 3B show averages of three AFC and pH measurements as a function of time.
- the results clearly show how solutions whose pH has been adjusted by adding gaseous carbon dioxide, and which therefore contain dissolved inorganic carbon (DIC, which can be in the form of carbonic acid or as a bicarbonate of an alkali or alkaline earth metal), are more stable over time, not only as regards their AFC content (more than 80 days were required to see a 50% reduction) but above all as regards the change in pH.
- Example 3 Hydrogel formulation
- a hydrogel formulation containing the stabilised solution of free chlorine was developed .
- the use of dissolved inorganic carbon in accordance with the invention has only a minimal effect on the ionic strength or electroconductivity of the solution.
- carbonic acid or bicarbonate do not affect the ionic strength at the targeted pH, making it possible to use hypochlorous acid with more than 300 ppm of available free chlorine as the dispersing media in a gel formulation, especially where low ionic strength is critical for the formulation.
- a low ionic strength hypochlorous acid solution (conductivity a 0.9 mS/cm), AFC 350 ppm, pH 6.1 was used for a hydrogel formulation containing 2% sodium magnesium fluorosilicate (Laponite XLG XR from BYK Additives Ltd).
- a low ionic strength HOCI solution as a dispersing media allows for the addition of other buffering agents for pH optimisation in the final product without negative effects on physical appearance and product stability.
Abstract
Description
Claims
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2022297975A AU2022297975A1 (en) | 2021-06-25 | 2022-05-10 | Stabilised hypohalous acid solutions |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2021901933A AU2021901933A0 (en) | 2021-06-25 | Stabilised Hypohalous Acid Solutions | |
AU2021901933 | 2021-06-25 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2022266698A1 true WO2022266698A1 (en) | 2022-12-29 |
Family
ID=84543773
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/AU2022/050440 WO2022266698A1 (en) | 2021-06-25 | 2022-05-10 | Stabilised hypohalous acid solutions |
Country Status (2)
Country | Link |
---|---|
AU (1) | AU2022297975A1 (en) |
WO (1) | WO2022266698A1 (en) |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015071995A1 (en) * | 2013-11-14 | 2015-05-21 | 古米 保 | Slightly-acidic aqueous hypochlorous acid solution containing ultrafine bubbles, method for producing same, and method for using same |
WO2016100543A2 (en) * | 2014-12-16 | 2016-06-23 | Puricore, Inc. | Hypochlorous acid formulations and methods for treating skin conditions |
US20200138953A1 (en) * | 2011-03-18 | 2020-05-07 | Urgo Us, Inc. | Stabilized hypohalous acid solutions |
JP2020143051A (en) * | 2019-02-28 | 2020-09-10 | 株式会社ナック | Hypochlorous acid aqueous solution |
CN112262853A (en) * | 2020-10-21 | 2021-01-26 | 李永琴 | Preparation method of slightly acidic carbonic acid type hypochlorous acid water disinfectant |
JP2021053546A (en) * | 2019-09-27 | 2021-04-08 | 合同会社Fmc | Manufacturing equipment and manufacturing method for carbonic acid-containing hypochlorous acid water |
CN113197783A (en) * | 2021-05-10 | 2021-08-03 | 云南君强企业管理有限公司 | Subacid hypochlorous acid disinfection wet tissue and preparation method thereof |
CN114569630A (en) * | 2020-12-02 | 2022-06-03 | 全鹏科技股份有限公司 | Disinfecting and sterilizing liquid, its production method and use |
-
2022
- 2022-05-10 WO PCT/AU2022/050440 patent/WO2022266698A1/en active Application Filing
- 2022-05-10 AU AU2022297975A patent/AU2022297975A1/en active Pending
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20200138953A1 (en) * | 2011-03-18 | 2020-05-07 | Urgo Us, Inc. | Stabilized hypohalous acid solutions |
WO2015071995A1 (en) * | 2013-11-14 | 2015-05-21 | 古米 保 | Slightly-acidic aqueous hypochlorous acid solution containing ultrafine bubbles, method for producing same, and method for using same |
WO2016100543A2 (en) * | 2014-12-16 | 2016-06-23 | Puricore, Inc. | Hypochlorous acid formulations and methods for treating skin conditions |
JP2020143051A (en) * | 2019-02-28 | 2020-09-10 | 株式会社ナック | Hypochlorous acid aqueous solution |
JP2021053546A (en) * | 2019-09-27 | 2021-04-08 | 合同会社Fmc | Manufacturing equipment and manufacturing method for carbonic acid-containing hypochlorous acid water |
CN112262853A (en) * | 2020-10-21 | 2021-01-26 | 李永琴 | Preparation method of slightly acidic carbonic acid type hypochlorous acid water disinfectant |
CN114569630A (en) * | 2020-12-02 | 2022-06-03 | 全鹏科技股份有限公司 | Disinfecting and sterilizing liquid, its production method and use |
CN113197783A (en) * | 2021-05-10 | 2021-08-03 | 云南君强企业管理有限公司 | Subacid hypochlorous acid disinfection wet tissue and preparation method thereof |
Non-Patent Citations (1)
Title |
---|
MARIN ET AL.: "Chlorinated wash water and pH regulators affect chlorine gas emission and disinfection by-products", INNOVATIVE FOOD SCIENCE & EMERGING TECHNOLOGIES, vol. 66, no. 102533, 2020, XP086389907, DOI: 10.1016/j.ifset.2020.102533 * |
Also Published As
Publication number | Publication date |
---|---|
AU2022297975A1 (en) | 2024-01-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10576152B2 (en) | Stabilized hypohalous acid solutions | |
US10702549B2 (en) | Methods for treating skin irritation | |
US20140328945A1 (en) | METHOD FOR STABILIZING AN ELECTROCHEMICALLY GENERATED SANITIZING SOLUTION HAVING A PREDETERMINED LEVEL OF FREE AVAILABLE CHLORINE AND pH | |
CN103501605B (en) | A stable composition of HOCl, processes for its production and uses thereof | |
US20090258083A1 (en) | Method of producing and applications of composition of hypochlorous acid | |
US11452778B2 (en) | Stabilized hypohalous acid solutions | |
WO2022266698A1 (en) | Stabilised hypohalous acid solutions | |
WO2022266699A1 (en) | Delivery device for a stabilised hypohalous acid solution |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22826874 Country of ref document: EP Kind code of ref document: A1 |
|
DPE1 | Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2022297975 Country of ref document: AU Ref document number: AU2022297975 Country of ref document: AU |
|
ENP | Entry into the national phase |
Ref document number: 2022297975 Country of ref document: AU Date of ref document: 20220510 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2022826874 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2022826874 Country of ref document: EP Effective date: 20240125 |